However, therapeutic targeting of IL-6 with clazakizumab demonstrated limited efficacy in improving enthesitis, dactylitis, or joint inflammation, with no clear dose-response relationship, leading to discontinuation of clinical trials (90). The gene discussed is IL6; the disease is enthesitis.